KS Biomedix Holdings plc believes that its technology for generating high-affinity sheep antibodies has benefits over competing antibody technologies. But the company's lack of a target identification capability has left its cupboard of actual antibody products relatively bare.

The company has moved to address its need for targets, products and cytotoxic antibody technology through its acquisition of Avicenna Inc., and deals with Human Antibody Sciences Inc. and Babraham Bioscience Technologies Ltd.